KOSDAQMachinery122310

Genoray

₩3,180▲ 3.41%2026-11-18 close
Market Cap
₩46.3B
Turnover
₩52,734,660
Volume
20K
Shares out.
14.6M
PER
20.4×
PBR
0.5×
EPS
₩154
Dividend Yield
4.78%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩150 per share · Prices as of the 2026-11-18 close

01

Report overview

Public tenders lift sales, but profit recovery is uneven by quarter

Annual sales rose for three straight years to KRW 108 billion in 2025, but operating profit turned into a loss that year, and quarterly profit has since alternated between gains and losses.

  1. 1

    Revenue grew for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

  2. 2

    The operating margin fell from 18.1% in 2022 to -0.2% in 2025, when the company posted an operating loss of KRW 243 million after turning negative.

  3. 3

    Third-quarter 2026 revenue was KRW 33.7 billion, up 54.3% year on year, and operating profit was KRW 2.7 billion. Net income attributable to controlling shareholders was a loss of KRW 1.74 billion in the same quarter.

  4. 4

    C-arm sales reached KRW 28 billion in the first half of 2026, or 53.9% of total revenue, while weaker dental CT demand weighed on profitability.

  5. 5

    Genoray supplied 130 units across two product lines through Turkish government tenders this year, and is pursuing CE certification and an ODM deal with Shimadzu Corporation to widen its sales channels.

02

Business structure

Genoray is a specialist maker of digital X-ray medical imaging equipment, founded in 2001. The business is split into medical and dental divisions, and by revenue in the second quarter of 2026 the medical division accounted for 64%, dental for 25%, and other businesses for 11%.

The medical division's core products are the mobile fluoroscopy unit known as the C-arm and mammography systems. C-arm sales reached KRW 28 billion of the KRW 52 billion consolidated revenue in the first half of 2026, or 53.9%.

The dental division centers on dental CT, and demand swings in this product have recently weighed on profitability. Sales are export-driven: according to a company press release from July 2024, 76% of revenue came from overseas.

The company says it supplies more than 80 countries through five overseas subsidiaries and about 150 partner companies. To widen overseas channels, it is pursuing government tenders alongside original design manufacturing (ODM) deals.

In Turkey, it built a record of supplying 130 units this year across mammography and mobile fluoroscopy lines. An industry source notes that government procurement has high entry barriers, but once delivery records accumulate, follow-on tenders become easier to win.

In April 2026 the company signed a C-arm ODM supply deal with Shimadzu Corporation of Japan and plans to sell through Shimadzu's global network from the third quarter.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩21.8B-₩1.7B−7.6%
2025Q4₩34B₩1.4B4.1%
2026Q1₩25.4B-₩1.6B−6.2%
2026Q2₩26.6B₩200M0.9%
2026Q3₩33.7B₩2.7B8.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩82.6B₩14.9B₩13.9B18.1%15.8%20.7%
2023₩97.9B₩12.8B₩12.5B13.0%13.1%30.1%
2024₩107B₩6.5B-₩1.8B6.1%−2.1%44.8%
2025₩108B-₩200M₩800M−0.2%0.9%56.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On the regular-filing basis, annual revenue rose from KRW 82.6 billion in 2022 to KRW 97.9 billion in 2023 (up 18.5%), KRW 107 billion in 2024 (up 9.3%), and KRW 108 billion in 2025 (up 1.0%), growing for three consecutive years from 2023 through 2025, with 2025 the largest year of 2022 to 2025.

Over the same period operating profit fell from KRW 14.9 billion to KRW 12.8 billion (down 14.5%) and KRW 6.51 billion (down 49.0%), and in 2025 the company posted an operating loss of KRW 243 million after turning negative. The operating margin declined from 18.1% to 13.0%, then 6.1%, and -0.2% in 2025.

Net income attributable to controlling shareholders went from KRW 13.9 billion in 2022 to KRW 12.5 billion in 2023 (down 10.2%), then a loss of KRW 1.8 billion in 2024, before returning to a KRW 758 million profit in 2025. Total net income including non-controlling interests was KRW 628 million in 2025.

The debt ratio rose from 20.7% in 2022 to 56.7% in 2025, when total liabilities were KRW 47.5 billion and total equity KRW 83.8 billion. Operating cash flow fell from KRW 13.3 billion in 2024 to KRW 5.26 billion in 2025.

By quarter, the company moved from an operating loss of KRW 1.66 billion in the third quarter of 2025 on KRW 21.8 billion revenue to an operating profit of KRW 1.38 billion on KRW 34 billion revenue in the fourth quarter, which it attributed to large government tender wins in Russia, Turkey and Lebanon.

First-quarter 2026 revenue fell 25.4% quarter on quarter to KRW 25.4 billion, with an operating loss of KRW 1.58 billion. Analysts attribute that quarter's weakness to dental CT sales declines that outweighed C-arm growth.

Operating profit returned to KRW 249 million in the second quarter and KRW 2.7 billion in the third, but the third quarter still showed a KRW 1.74 billion net loss attributable to controlling shareholders. Net income attributable to controlling shareholders over the latest four quarters totaled KRW 1.86 billion.

05

Industry analysis

Genoray's main markets combine demand for medical imaging driven by population aging with government procurement in each country. Demand for C-arm systems is described as steady because of aging populations. Dental CT, by contrast, has volatile demand, which has weighed on the dental division's profitability.

Industry commentary holds that government-procurement markets have high entry barriers, but once a supplier wins a tender, follow-on orders and entry into adjacent product lines become easier. Turkey is known as a market where the government buys medical equipment in bulk and distributes it to public hospitals.

The company is building government project experience largely through its Turkish subsidiary and widening its product range. Tender wins in Russia, Turkey and Lebanon were reflected in fourth-quarter 2025 results.

Winning tenders depends as much on track record and certifications as on product specifications, and the company is pursuing CE certification to expand the countries where it can bid. In China, dental CT supply is conditional on local certification, so the timing of approval determines when sales can begin. Where its own sales network is thin, the company is leaning on Shimadzu's global network.

06

Outlook

The company's stated plans fall into three areas. First, it announced a new contract win worth about KRW 17 billion in early 2026. Second, it is pursuing CE certification to widen the countries where it can bid in global tenders.

Third, it is seeking local registration in Turkey for new products to broaden its portfolio for government procurement. Sales through Shimadzu's global network were planned to begin in the third quarter of 2026, and whether that shows up in results is a point to track.

The company says it has finished its production and research infrastructure investment, reducing the burden of further large capital spending, and it aims to raise sales and improve its cost structure. It has also set a target of raising the share of government tender sales to 15% or more.

Revenue rose for two straight quarters to KRW 33.7 billion in the third quarter of 2026, but whether operating profit stays positive quarter after quarter remains to be seen in upcoming results. Recovery in dental CT demand is the key variable for profitability.

The planned large-scale Chinese dental CT supply depends on local certification, so its timing is uncertain. Whether these items materialize will set the reference point for earnings trends after 2027.

07

Valuation

PER
20.4×
PBR
0.5×
ROE
2.4%
EPS
₩154
BPS
₩6,228
Dividend per share
₩150

Valuation is best read by weighing the current share price against the size of earnings. Net income attributable to controlling shareholders over the latest four quarters totaled KRW 1.86 billion, a small base, so the price-to-earnings multiple is sensitive to changes in profit.

By contrast, the price-to-book multiple sits in the range where the share price trades at a discount to net assets. Total equity at the end of 2025 was KRW 83.8 billion, of which KRW 84.5 billion was attributable to controlling shareholders.

The company says it pairs tax-free dividends with a capital-reserve reduction method, and the dividend yield moves with the share price. Operating cash flow, which funds dividends, fell from KRW 13.3 billion in 2024 to KRW 5.26 billion in 2025.

The key questions for valuation are therefore whether profit recovery holds quarter after quarter and whether cash flow can support the dividend.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Wider government tender wins

Genoray secured all major Turkish government mammography tenders for 2026 and, together with mobile fluoroscopy units, built a record of supplying 130 units across two product lines. Large government tender wins in Russia, Turkey and Lebanon were reflected in fourth-quarter 2025 revenue. The company said it signed a new contract worth about KRW 17 billion in early 2026.

Quarterly recovery trend

Revenue bottomed at KRW 25.4 billion in the first quarter of 2026, then rose to KRW 26.6 billion in the second and KRW 33.7 billion in the third. Third-quarter operating profit of KRW 2.7 billion turned positive compared with a year earlier. Operating profit had also turned positive in the fourth quarter of 2025, at KRW 1.38 billion.

Wider sales channels and certifications

The C-arm ODM agreement with Shimadzu Corporation opens a route through a Japanese company's global sales network. The company plans to widen the countries where it can bid by securing CE certification.

In its investor-relations material, it said completing production and research infrastructure investment reduces the burden of further large capital spending.

09

Bear factors

A clear decline in profitability

The operating margin fell from 18.1% in 2022 to 13.0% in 2023, 6.1% in 2024, and -0.2% in 2025. The company posted an operating loss of KRW 243 million in 2025.

In the third quarter of 2026, operating profit was positive but net income attributable to controlling shareholders was a loss of KRW 1.74 billion, leaving a gap between profit measures.

Weakness in the dental division

In the first quarter of 2026, lower dental CT sales pulled down gross profit and operating profit. In the first half of 2026, major medical products added about KRW 4 billion in sales, but major dental products lost about KRW 3.2 billion. Because dental CT demand is volatile, medical growth could again be offset.

Financial burden and cash flow

The debt ratio rose from 20.7% in 2022 to 56.7% in 2025, when total liabilities stood at KRW 47.5 billion. The U.S. subsidiary Genoray America posted a net loss of KRW 840 million in the first half of 2026.

10

Risk factors

Reliance on government tenders

Overseas sales are a high share of revenue, and much of that depends on government tenders in individual countries, so quarterly revenue can swing sharply with tender timing and award outcomes. The KRW 34 billion revenue in the fourth quarter of 2025 reflected tender wins in Russia, Turkey and Lebanon. If tender wins cluster in one quarter, revenue in the following quarter can fall.

Currency and country conditions

According to a July 2024 company press release, 76% of revenue came from overseas, so currency movements and political or fiscal conditions in export markets feed directly into results. Losses at overseas subsidiaries also weigh on consolidated profit, as Genoray America's net loss in the first half of 2026 shows.

Chinese certification and dental CT supply

The dental CT agreement with HMD of China envisions supplying about KRW 50 billion over five years, starting from the point when Chinese certification is obtained. If certification is delayed, the supply timeline slips accordingly. If dental CT demand keeps falling, growth in the medical division could be offset.

11

What to watch next

  1. December 31, 2026 (fiscal year-end)

    This is the cut-off for fourth-quarter 2026 results. Whether dental CT demand recovers from the first-quarter decline and whether local registration of new products in Turkey advances will feed into subsequent results.

  2. Around February 2027

    This is when fourth-quarter 2026 preliminary results are expected. Fourth-quarter 2025 preliminary results were disclosed on February 12, 2026. The check point is whether quarterly operating profit stays positive.

  3. End of March 2027

    This is the filing deadline for the 2026 annual report. It is the formal disclosure that shows whether the annual operating margin recovered from -0.2% in 2025 and how the 56.7% debt ratio changed.

  4. Timing not yet announced

    The key items are whether CE certification and Chinese dental CT certification are obtained. Both are prerequisites for expanding the countries where Genoray can bid and for its planned Chinese supply.

12

Overall view

Genoray's annual revenue reached KRW 108 billion in 2025 and has grown since 2022, but the operating margin fell from 18.1% to -0.2%. The company posted an operating loss of KRW 243 million in 2025 after turning negative, while net income attributable to controlling shareholders turned positive at KRW 758 million.

In 2026, revenue rose for two straight quarters after bottoming in the first quarter, and third-quarter operating profit of KRW 2.7 billion turned positive. The same third quarter showed a net loss attributable to controlling shareholders of KRW 1.74 billion, so profit measures diverged.

Strengths are the government tender record in C-arm and mammography systems and the diversification of overseas channels. Weaknesses are volatile dental CT demand and a debt ratio that rose from 20.7% in 2022 to 56.7% in 2025.

The next checkpoints are preliminary fourth-quarter 2026 results and the operating margin in the 2026 annual report. The timing of CE and Chinese certifications is also a variable for how fast overseas awards can grow. This report is for information only and does not include an investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.fnguide.com
  2. medipana.com
  3. thevc.kr
  4. news.nate.com
  5. news.nate.com
  6. fnnews.com
  7. fnnews.com
  8. jobplanet.co.kr
  9. jobplanet.co.kr
  10. butler.works
  11. m.irgo.co.kr
  12. catch.co.kr
  13. biobookmedia.com
  14. datatooza.com
  15. datatooza.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis